• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20001 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy for insomnia - Evidence report for the S3 guideline on non-restorative sleep/sleep disorders - Insomnia in adults]
2008     Center for Medical Technology Assessment (CMT) [Cognitive assistive technologies for persons with dementia - cost-effectiveness and quality of prescription process]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cobimetinib: addendum to commission A15-52]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cobimetinib - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cobicistat (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [CoaguChek XS PT TEST]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [CO2 Laser surgery in patients with otosclerosis]
2019     Basque Office for Health Technology Assessment (OSTEBA) [Closed vs open systems for the preparation and administration of cytostatic and other hazardous drugs (NIOSH Group 1): analysis of the scientific evidence, costs and organisational requirements]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Clinically relevant venous thromboembolism following hip and knee arthroplasty]
2013     Haute Autorite de sante (HAS) [Clinical utility of the measurement of vitamin D]
2021     Andalusian Health Technology Assessment Area (AETSA) [Clinical utility of optical coherence tomography angiography in exudative age-related macular degeneration management]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Clinical safety and effectiveness of robotic surgery (2)]
2020     Basque Office for Health Technology Assessment (OSTEBA) [Clinical Practice Guidelines on the diagnosis and treatment of non-serious blunt chest trauma]
2018     Andalusian Health Technology Assessment Area (AETSA) [Clinical practice guidelines on severe mental disorder]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guidelines on lipid management as a cardiovascular risk factor]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guidelines on arterial hypertension (2007 update)]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Clinical practice guidelines for the rehabilitation of adults having sustained a moderate to severe traumatic brain injury: development process and recommendations]
2017     Andalusian Health Technology Assessment Area (AETSA) [Clinical practice guidelines for hemotherapy. Brief report]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on type 2 diabetes]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on type 1 diabetes]
2017     Andalusian Health Technology Assessment Area (AETSA) [Clinical practice guideline on the management of vasomotor and vaginal symptoms associated with menopause and postmenopause]
2007     Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on the management of head injury in the field of extra and initial hospital care]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Clinical practice guideline on the diagnostic, treatment and prevention of tuberculosis]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Clinical Practice Guideline on the care for people with alzheimer's disease and dementia]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Practice Guideline on prevention and management of suicidal behaviour]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on palliative care]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Clinical practice guideline on osteoporosis and prevention of fragility fractures]
2007     Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on low back pain]
2014     Andalusian Health Technology Assessment Area (AETSA) [Clinical practice guideline on intravenous therapy with temporary devices in adults]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Clinical Practice Guideline on Childhood Asthma]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Clinical practice guideline on borderline personality disorders]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on asthma]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on assistance at normal childbirth]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Practice Guideline on adult's palliative care]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Clinical practice guideline on acute bronchiolitis]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Clinical practice guideline of care for people with multiple sclerosis]
2001     Andalusian Health Technology Assessment Area (AETSA) [Clinical practice guideline for medical management of otitis media in childhood]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Clinical practice guideline for attention deficit hyperactivity disorder (ADHD) in children and adolescents]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Clinical Practice Guideline about breastfeeding]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical impact of capsule endoscopy in obscure gastrointestinal bleeding. Systematic review]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Clinical guides in antibiotic treatment, 2nd series]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Clinical guides in antibiotic treatment – 1st series (update)]
2022     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Clinical effectiveness of pulse oximetry for neonatal screening of critical congenital heart diseases]
2009     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness of ozone therapies]
2009     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness of ozone therapies]
2018     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for severe combined immunodeficiency]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism. Part II: Methylmalonic acidemia, Propionic acidemia, Tyrosinemia type I]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: β-ketothiolase deficiency (BKT); 3-hydroxy-3-methyl glutaric aciduria (HMG)]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: Beta-kethiolase deficiency (BKT); 3-Hydroxy-3-methyl glutaric aciduria (HMG)]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part III: carnitine uptake deficiency (CUD); short-chain acyl-CoA dehydrogenase deficiency (SCADD); very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry: Maple Syrup Urine Disease, Homocystinuria, Glutaric Aciduria Type I, Isovaleric Acidaemia, Long-chain 3-Hydroxyacyl CoA Dehydrogenase Deficiency]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry. Systematic Review]
2005     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Clinical effectiveness of indapamide; systematic review of the clinical and economic literature]
2005     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Clinical effectiveness of carvedilol in comparison to -blockers, systematic review of the clinical and economic literature]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Clinical effectiveness and safety of robotic surgery]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Clinical effectiveness and cost-effectiveness of non-invasive telemonitoring on patients with heart failure]
2014     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Clinical effectiveness and cost-effectiveness of fissure sealants in children and adolescents with a high caries risk]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Clinical effectiveness and cost-effectiveness of central venous catheters treated with minocycline and rifampicin in preventing bloodstream infections in intensive care patients]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Efectiveness of Newborn Screening for Inborn Errors of Metabolism by MS/ MS. Update and pilot study assessment: Maple Syrup Urine Disease; Isovaleric Acidaemia; Homocystinuria]
2008     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Clavicular fractures - a systematic review about efficacy and safety of different treatment options]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Classification of disease severity for neuro- and trauma rehabilitation Part 3: Status quo in Austria]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Circulating tumour cells in breast cancer: clinical use of the CellSearch® test]
2010     The Swedish Council on Health Technology Assessment (SBU) [Cilostazol for treatment of intermittent claudication]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Cidofovir for the treatment of recurrent respiratory papillomatosis]
2014     The Swedish Council on Health Technology Assessment (SBU) [Chronic ulcers in the elderly – prevention and treatment]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Chronic periodontitis - prevention, diagnosis and treatment]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Chronic low back pain: the appropriate use of diagnostic imaging procedures]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Chronic hepatitis C. Combination therapy IFN and ribavirin]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Chronic fatigue syndrome: state of the evidence and assessment of intervention modalities in Quebec]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Chromosomal microarrays for the etiologic diagnosis in patients with intellectual disability, developmental delay or autism spectrum]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [ChondroCelect® in patients with knee cartilage injury]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Chlamydia screening with home testing - a health technology assessment]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Chemoembolization and radioembolization for the treatment of liver metastases]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Checklist for ethical and legal domains analysis]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Cetuximah given in combination for patients with colorectal cancer]
2010     Haute Autorite de sante (HAS) [Cervical length measurement with transvaginal ultrasonography to predict spontaneous preterm birth]
2017     Agenzia nazionale per i servizi sanitari regionali (Agenas) [Cervical and lumbar total disc replacement - HTA report adaptation]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Cerliponase alfa in neuronal ceroid lipofuscinosis type 2]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cerliponase alfa (neuronal ceroid lipofuscinosis) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Ceritinib in lung cancer]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Ceritinib for the treatment of ALK-positive metastatic non-small cell lung cancer]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (lung cancer): benefit assessment according to §35a Social Code Book V; expiry of the decision
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib (lung cancer): Addendum to Commission A16-62]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Cerebrospinal fluid neurotransmitter screening in encephalopathies]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Centralized Implementation of accurate and efficient preoperative staging using multislice CT, endoultrasonographic fine needle biopsy (EUS-FNA) and positron emission tomography (FDG-PET) in esophageal cancer patients: Cimple study]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Central auditory processing disorder diagnosis]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenobamate (epilepsy) - Benefit assessment according to §35a Social Code Book]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenobamate (epilepsy) - Addendum to Commission A21-78]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenegermin (moderate or severe neurotrophic keratitis) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (hospital-acquired pneumonia) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (complicated urinary tract infections) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftolozane/tazobactam (complicated intra-abdominal infections) - Benefit assessment according to §35a Social Code Book V]